Cardiol Therapeutics (TSE:CRDL) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cardiol Therapeutics Inc., a clinical-stage life sciences company, has announced their virtual Annual General and Special Meeting of Shareholders to be webcasted on June 26, 2024. The company, known for its development of anti-inflammatory and anti-fibrotic therapies for heart disease, is advancing clinical studies of its lead drug, CardiolRx™, with FDA approval for trials in pericarditis and myocarditis. Cardiol is also progressing with CRD-38, a new drug formulation aimed at treating heart failure, a major cause of mortality and hospitalization.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.